+ All Categories
Home > Documents > Objectives To introduce the terminology used in describing the plasma cells neoplasm. To explain the...

Objectives To introduce the terminology used in describing the plasma cells neoplasm. To explain the...

Date post: 21-Dec-2015
Category:
View: 218 times
Download: 1 times
Share this document with a friend
Popular Tags:
23
Transcript

Objectives

• To introduce the terminology used in describing the plasma cells neoplasm.

• To explain the physiology of the normal cells & the pathological effects of their neoplastic growth.

• To describe the classification of plasma cells neoplasm.

• To discuss the relationship with amyloidosis and its pathology.

Plasma cells

Terminally differentiated B- Lymphocytes that are

capable of producing immunoglobulins.

• Paraprotein :

Structurally identical & homologous ig.of the same clone i.e monoclonal.

• Lymphoplasmacytic Neoplasm :

Neoplasm of the plasma cells producing excess paraprotein.

Classification of plasma cell neoplasms

• Monoclonal gammopathy of undetermined significance.

• Multiple myeloma.

• Macroglobulinemia.

Monoclonal gammopathy of undetermined significance ( MGUS)

• M protein presence, stable

• levels of M protein: IgG < 3,5g IgA < 2g LC<1g/day

• normal immunoglobulins - normal levels

• marrow plasmacytosis < 5%

• complete blood count - normal

• no lytic bone lesions

• no signs of disease

Monoclonal gammopathy of undetermined significance ( MGUS)

• M protein– 3% of people > 70 years– 15% of people > 90 years– MGUS is diagnosed in 67% of patients with an M

protein– 10% of patients with MGUS develop multiple

myeloma

Macroglobulinemia Tumour of lymphoplasmacytoid cells producing

Monoclonal ig most commonly ( Igm )

Types : - Essential macroglobulinemia.

- waldenstrom macroglobulinemia.

Clinical Features :• Weight loss, fatigue.• Bleeding usually epistaxis.• Bone marrow infiltration by the lymphoplasmcytic cells “less

mature than plasma cells” presenting as anemia thrombocytopenia or leucopenia.

Multiple Myeloma

• Definition:

B-cell malignancy characterised by abnormal proliferation of plasma cells able to

produce a monoclonal immunoglobulin ( M protein ) • Incidence:

3 - 9 cases per 100000 population / year

more frequent in elderly

modest male predominance

Multiple Myeloma

• Clinical forms: multiple myeloma solitary plasmacytoma plasma cell leukemia

• M protein:- is seen in 99% of cases in serum and/or urine

IgG > 50%, IgA 20-25%, IgE i IgD 1-3%light chain 20%

- 1% of cases are nonsecretory

Multiple Myeloma

Clinical manifestations are related to malignant behavior of plasma cells and abnormalities produced by M protein

• plasma cell proliferation:multiple osteolytic bone lesionshypercalcemiabone marrow suppression ( pancytopenia )

• monoclonal M proteindecreased level of normal immunoglobulinshyperviscosity

Multiple Myeloma

Clinical symptoms:

• bone pains, pathologic fractures• weakness and fatigue • serious infection • renal failure• bleeding diathesis

Multiple Myeloma

Laboratory tests:

• ESR > 100

• anaemia, thrombocytopenia

• rouleaux in peripheral blood smears

• marrow plasmacytosis > 10 -15%

• hyperproteinemia

• hypercalcemia

• proteinuria

• azotemia

Diagnostic Criteria for Multiple Myeloma

Major criteria

I. Plasmacytoma on tissue biopsy

II. Bone marrow plasma cell > 30%

III. Monoclonal M spike on electrophoresis IgG > 3,5g/dl,

IgA > 2g/dl, light chain > 1g/dl in 24h urine sample

Minor criteria

a. Bone marrow plasma cells 10-30%

b. M spike but less than above

c. Lytic bone lesions

d. Normal IgM < 50mg, IgA < 100mg, IgG < 600mg/dl

Diagnostic Criteria for Multiple Myeloma

Diagnosis:

• I + b, I + c, I + d • II + b, II + c, II + d• III + a, III + c, I II + d• a + b + c, a +b + d

Staging of Multiple Myeloma

Clinical staging • is based on level of haemoglobin, serum calcium,

immunoglobulins and presence or not of lytic bone lesions

• correlates with myeloma burden and prognosis I. Low tumor mass II. Intermediate tumor mass

III. High tumor mass• subclassification

A - creatinine < 2mg/dlB - creatinine > 2mg/dl

Multiple Myeloma

Poor prognosis factors

• cytogenetical abnormalities of 11 and 13 chromosomes

• beta-2 microglobulines > 2,5 ug/ml

Treatment of Multiple Myeloma

• Patients < 65 - 70 years – high-dose therapy with autologous stem cell

transplantation– allogeneic stem cell transplantation ( conventional

and „mini”)• Patients > 65 years

– conventional chemotherapy– non-myeloablative therapy with allogeneic

transplantation („mini”)

Treatment of Multiple Myeloma

• Conventional chemotherapy– Melphlan + Prednisone– M2 ( Vincristine, Melphalan, Cyclophosphamid,

BCNU, Prednisone)– VAD (Vincristin, Adriamycin, Dexamethasone)

• Response rate 50-60% patients• Long term survival 5-10% patients

Treatment of Multiple Myeloma

• Autologous transplantation

– patients < 65-70 years

– treatment related mortality 10-20%

– response rate 80%

– long term survival 40-50%

• Conventional allogeneic transplantation

– patients < 45-50 years with HLA-identical donor

– treatment related mortality 40-50%

– long term survival 20-30%

Treatment of Multiple Myeloma

• New method

– non-myeloablative therapy and allogeneic transplantation

– thalidomid

Treatment of Multiple Myeloma

• Supportive treatment

– biphosphonates, calcitonin

– recombinant erythropoietin

– immunoglobulins

– plasma exchange

– radiation therapy

Disorder Associated with Monoclonal Protein

• Neoplastic cell proliferation– multiple myeloma– solitary plasmacytoma– Waldenstrom macroglobulinemia– heavy chain disease– primary amyloidosis

• Undetermined significance– monoclonal gammopathy of undetermined significance (MGUS)

• Transient M protein– viral infection– post-valve replacement

• Malignacy– bowel cancer, breast cancer

• Immune dysregulation– AIDS, old age

• Chronic inflammation

Amyloidosis • Primary amyloidosis : Deposition of light chain of Ig as in multiple myeloma sites

: Tongue, GIT, Heart, Connective tissue. • Secondary Amyloidosis : Deposition of amyloid -A- substance Sites : Spleen, Liver, Kidney • Familial Amyloidosis: Due to genetic mutation Causing deposition of unmetalised prealbumin.


Recommended